Nanjing Vazyme Biotech Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	426.17	804.9	434.25	1,967	1,545	1,478
Trading Asset Securities	2,085	2,049	2,222	1,514	1,719	1,976
Cash & Short-Term Investments	2,512	2,854	2,656	3,481	3,264	3,454
Cash Growth	-13.75%	7.45%	-23.69%	6.65%	-5.49%	239.50%
Accounts Receivable	467.15	460.05	483.61	351.93	839.62	322.32
Other Receivables	9.52	11.56	20.81	4.07	7.72	4.67
Receivables	476.67	471.61	504.42	356.01	847.35	326.99
Inventory	349.63	343.67	362.18	346.25	364.2	242.19
Prepaid Expenses	3.31	2.13	0.05	-	-	-
Other Current Assets	34.38	36.14	48.58	47.12	89.71	28.1
Total Current Assets	3,376	3,708	3,571	4,230	4,565	4,051
Property, Plant & Equipment	579.88	617.48	726.07	767.3	679.48	308.98
Long-Term Investments	76.17	79.96	54.83	47.3	22.31	18.48
Goodwill	130.49	130.49	130.49	130.49	130.49	-
Other Intangible Assets	80.07	86.63	95.19	101.24	49.7	16.65
Long-Term Accounts Receivable	0.35	0.06	0.15	-	-	-
Long-Term Deferred Tax Assets	178.04	166.62	146.04	106.51	67.12	24.87
Long-Term Deferred Charges	194.98	220.12	278.91	280.54	318.31	145
Other Long-Term Assets	15.75	19	45.51	82.53	172.69	42.25
Total Assets	4,631	5,028	5,049	5,746	6,005	4,607

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	97.66	91.59	90.4	146.82	318.78	118.76
Accrued Expenses	106.57	142.43	129.74	112.52	258.07	104.7
Short-Term Debt	525.27	686.68	551.32	1,134	272.21	-
Current Portion of Leases	36.21	28.43	57.03	46.16	58.25	31.25
Current Income Taxes Payable	0.89	2.23	0.6	0.03	0.54	20.02
Current Unearned Revenue	59.86	72.14	54.87	55.92	214.55	95.03
Other Current Liabilities	19.21	18.36	19.36	24.09	31.67	17.5
Total Current Liabilities	845.66	1,042	903.33	1,520	1,154	387.26
Long-Term Leases	110.09	127.33	143.36	106.89	127.68	59.93
Long-Term Unearned Revenue	66.86	61.76	48.38	21.38	19.25	16.24
Long-Term Deferred Tax Liabilities	1.55	1.03	1.26	1.51	11.19	0.87
Other Long-Term Liabilities	4.85	4.75	8.72	67.6	80.92	15.52
Total Liabilities	1,029	1,237	1,105	1,717	1,393	479.83

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	516.99	397.73	402.13	400.01	400.01	400.01
Additional Paid-In Capital	2,223	2,339	2,512	2,442	2,429	2,422
Retained Earnings	875	1,063	1,139	1,209	1,780	1,305
Treasury Stock	-5.01	-3	-104.4	-20.01	-	-
Comprehensive Income & Other	0.16	-0.63	-3.97	-1.72	-	-
Total Common Equity	3,610	3,796	3,945	4,029	4,609	4,127
Minority Interest	-7.55	-4.82	-1.63	-0.11	3.2	-
Shareholders' Equity	3,602	3,791	3,944	4,029	4,612	4,127
Total Liabilities & Equity	4,631	5,028	5,049	5,746	6,005	4,607

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	671.57	842.44	751.71	1,287	458.14	91.18
Net Cash (Debt)	1,840	2,012	1,905	2,194	2,806	3,362
Net Cash Growth	1.74%	5.62%	-13.19%	-21.81%	-16.56%	230.91%
Net Cash Per Share	3.21	3.73	4.05	4.28	5.41	7.13
Filing Date Shares Outstanding	516.99	517.05	517.16	516.1	520.01	520.01
Total Common Shares Outstanding	516.99	517.05	517.16	516.1	520.01	520.01
Working Capital	2,530	2,666	2,668	2,711	3,411	3,664
Book Value Per Share	6.98	7.34	7.63	7.81	8.86	7.94
Tangible Book Value	3,399	3,579	3,720	3,798	4,429	4,111
Tangible Book Value Per Share	6.58	6.92	7.19	7.36	8.52	7.90
Machinery	739.34	720.6	712.88	656.11	513.97	250.31
Construction In Progress	63.91	63.86	69.42	127.48	69.44	-